Domperidone prolongs oral to duodenal transit time in video capsule endoscopy
- 280 Downloads
Domperidone is thought to accelerate gastric emptying via D2 receptor antagonism at the gastro-oesophageal and gastro-duodenal junctions. Listed in the BNF as a prokinetic anti-emetic, it has been used in video capsule endoscopy (VCE) to accelerate capsule delivery to the small intestine. We audited VCEs performed at UHCW from 2011, when as standard practice, domperidone was given pre-VCE, to 2012, after its discontinuation due to doubts about its effectiveness.
Thirty-one patients received oral domperidone 20 mg pre-VCE. Thirty-three patients underwent VCE without domperidone pre-treatment. After 2 h, if the capsule remained intra-gastric, gastroscopy-assisted duodenal delivery was performed. Data was analysed using Mann-Whitney testing.
Median oro-duodenal transit was 13 and 30 min in the untreated and domperidone groups, respectively (p = 0.01). Median oro-caecal transit was 242 and 267 min in the untreated and domperidone groups, respectively (p = 0.02). No difference in duodenal-caecal transit was seen (p = 0.60). Six percent of untreated and 13% of domperidone VCEs required gastroscopy-assisted duodenal capsule delivery (p = 0.65).
Unexpectedly domperidone delayed VCE gastric transit. Most studies on domperidone prokinetic effects have been in diabetic gastroparesis, demonstrating that domperidone can achieve good symptomatic relief, but with mixed results for gastric emptying. Our study suggests that any antiemetic effects of domperidone are not mediated through accelerated gastric transit.
KeywordsCapsule endoscopy Domperidone Prokinetic Gastric transit
MM: Analysed the data and wrote the manuscript
BL: Collected the data
CN: Wrote the manuscript and project oversight
Compliance with ethical standards
The authors declare that they have no competing interests.
- 1.Sneader W (2006) Drug discovery—a history. John Wiley & Sons, HobokenGoogle Scholar
- 4.Shuto K, Shiozaki Z, Kojima T, Tanaka M (1980) Antagonism of KW-5338 (domperidone) against emesis and depression of intestinal motility induced by L-DOPA. Aust J Pharm 3(12):709–714Google Scholar
- 5.Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24(5):360–400. https://doi.org/10.2165/00003495-198224050-00002 CrossRefPubMedGoogle Scholar
- 7.Joint Formulary Committee (2016) British National Formulary. BMJ Group and Pharmaceutical Press, LondonGoogle Scholar
- 11.Bateman DN, Gooptu D, Whittingham TA (1982) The effects of domperidone on gastric emptying of liquid in man. Br J Clin Pharmacol 13(5):675–678. https://doi.org/10.1111/j.1365-2125.1982.tb01435.x CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F (2004) Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 19(4):379–390. https://doi.org/10.1111/j.1365-2036.2004.01867.x CrossRefPubMedGoogle Scholar
- 16.Sweetser S, Ravi K (2013) Gastrointestinal motility. In: DeCross AJ (ed) DDSEP7 Digestive Diseases Self-Education Program. AGA, Bethesda, pp 53–85Google Scholar